ALX ONCOLOGY HOLDINGS INC Finance Lease, Principal Payments
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Finance Lease, Principal Payments of $543.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for the quarter ending 2026-06-30 was $236.00K, a 0.42% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for the quarter ending 2026-03-31 was $307.00K, a 0.00% change year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for the quarter ending 2025-12-31 was $225.00K, a 196.05% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for the quarter ending 2025-09-30 was $160.00K, a 55.31% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for fiscal 2025 was $929.00K, a 12.33% increase from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for fiscal 2024 was $827.00K, a 113.14% increase from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for fiscal 2023 was $388.00K, a 0.00% change from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC finance lease, principal payments for fiscal 2022 was $388.00K, a 38.08% increase from fiscal 2021.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $236.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $543.00K 10-Q · filed 2026-08-06 | $768.00K derived: sum of 3 quarters · filed 2026-08-06 | $928.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $307.00K 10-Q · filed 2026-05-08 | $532.00K derived: sum of 2 quarters · filed 2026-05-08 | $692.00K derived: sum of 3 quarters · filed 2026-05-08 | $929.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $385.00K derived: sum of 2 quarters · filed 2026-03-09 | $622.00K derived: sum of 3 quarters · filed 2026-08-06 | $929.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $160.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $397.00K derived: sum of 2 quarters · filed 2026-08-06 | $704.00K 10-Q · filed 2025-11-07 | $780.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $237.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $544.00K 10-Q · filed 2026-08-06 | $620.00K derived: sum of 3 quarters · filed 2026-08-06 | $978.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $307.00K 10-Q · filed 2026-05-08 | $383.00K derived: sum of 2 quarters · filed 2026-05-08 | $741.00K derived: sum of 3 quarters · filed 2026-05-08 | $959.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $434.00K derived: sum of 2 quarters · filed 2026-03-09 | $652.00K derived: sum of 3 quarters · filed 2026-03-09 | $827.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $576.00K derived: sum of 2 quarters · filed 2025-11-07 | $751.00K 10-Q · filed 2025-11-07 | $814.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $218.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $393.00K 10-Q · filed 2025-08-12 | $456.00K derived: sum of 3 quarters · filed 2026-03-09 | $567.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $175.00K 10-Q · filed 2025-05-08 | $238.00K derived: sum of 2 quarters · filed 2026-03-09 | $349.00K derived: sum of 3 quarters · filed 2026-03-09 | $456.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $174.00K derived: sum of 2 quarters · filed 2026-03-09 | $281.00K derived: sum of 3 quarters · filed 2026-03-09 | $388.00K 10-K · filed 2026-03-09 |
| 2023-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $218.00K derived: sum of 2 quarters · filed 2024-11-07 | $325.00K 10-Q · filed 2024-11-07 | $432.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $214.00K 10-Q · filed 2024-08-12 | $321.00K derived: sum of 3 quarters · filed 2025-03-06 | $462.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $107.00K 10-Q · filed 2024-05-09 | $214.00K derived: sum of 2 quarters · filed 2025-03-06 | $355.00K derived: sum of 3 quarters · filed 2025-03-06 | $390.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $248.00K derived: sum of 2 quarters · filed 2025-03-06 | $283.00K derived: sum of 3 quarters · filed 2025-03-06 | $388.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $176.00K derived: sum of 2 quarters · filed 2023-11-13 | $281.00K 10-Q · filed 2023-11-13 | $385.00K derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $140.00K 10-Q · filed 2023-08-10 | $244.00K derived: sum of 3 quarters · filed 2024-03-07 | $348.00K derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $105.00K 10-Q · filed 2023-05-11 | $209.00K derived: sum of 2 quarters · filed 2024-03-07 | $313.00K derived: sum of 3 quarters · filed 2024-03-07 | |
| 2021-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $208.00K derived: sum of 2 quarters · filed 2024-03-07 | $281.00K 10-K · filed 2024-03-07 | |
| 2021-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $177.00K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $73.00K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |